Specific CD4 down-modulating compounds with potent anti-HIV activity

摘要: Despite the availability of current clinically approved anti-HIV drugs, new classes effective antiviral agents are still urgently needed to combat AIDS. A promising approach for drug development and vaccine design involves targeting research on HIV-1 entry, a multistep process that comprises viral attachment, coreceptor interac- tions, fusion. Determination entry in detail has enabled specific can inhibit each step HIV process. Therapeutic interfere with binding envelope glycoprotein gp120 CD4 receptor (e.g., PRO 542, 2000, CV-N) or coreceptors CCR5 CXCR4 SCH-C AMD3100) briefly outlined this review. The activity cyclotriazadisul- fonamides, novel class compounds unique mode action by down-modulating lymphocytic monocytic cells, is especially highlighted. On basis suc- cessful results T-20, first inhibitor, antiretrovi- rals block will certainly be further encouraged. J. Leukoc. Biol. 74: 667-675; 2003.